Teva's Anti-IL-15 Antibody Clears Phase 2 in Celiac Disease

Teva Pharmaceutical said its anti-interleukin-15 antibody succeeded in a phase 2 trial in celiac disease, keeping alive the Israeli drugmaker's ambition for a first-in-class autoimmune blockbuster; Teva shares last traded at 36.36, down 0.71% on Sept. 4, 2026.

Teva Pharmaceutical (TEVA) has a midstage win in one of the hardest indications in autoimmune medicine. The Israeli drugmaker said its antibody against interleukin-15 succeeded in a phase 2 trial in celiac disease, an outcome that keeps intact the company's pitch that it is holding a potential first-in-class autoimmune blockbuster rather than another line extension.

The result was reported by Fierce Biotech. It matters for two separate reasons that are worth keeping apart: what it says about interleukin-15 as a drug target, and what it says about Teva's attempt to rebuild an innovative pipeline on top of a generics business.

Why interleukin-15 is the target in celiac disease

Celiac disease is an immune reaction to gluten that damages the lining of the small intestine. The only management available to patients is dietary: strict, permanent avoidance of wheat, barley and rye. That is harder in practice than it sounds, because gluten turns up in trace amounts across the food supply, and many patients continue to show intestinal damage and symptoms even when they believe they are adhering to the diet. There is no approved drug that treats the underlying disease.

Interleukin-15 is a signalling protein — a cytokine — that helps activate and sustain certain immune cells. In celiac disease it has long been implicated in the process by which intraepithelial lymphocytes, immune cells resident in the gut lining, turn destructive against the intestinal surface. Blocking it with an antibody is an attempt to interrupt the tissue-damage step rather than the gluten-recognition step. That is a different mechanistic bet from the enzyme therapies and gluten-degrading approaches that have dominated earlier attempts in this field, several of which have failed to convert promising biology into a clean clinical result.

That history is the reason a positive phase 2 in celiac is treated as a genuine event rather than a routine pipeline update. The indication has an unusually long list of programs that read out ambiguously or missed outright, and biopsy-based endpoints in the gut have proven difficult to move consistently.

The commercial case, and why "first-in-class" is the operative phrase

Being first in class means arriving in a market with no approved competitor and, in this case, a very large diagnosed and undiagnosed patient population that currently has nothing to buy. That combination is what supports blockbuster language — the industry shorthand for a drug generating $1 billion or more in annual sales. Nothing in the phase 2 result guarantees Teva gets there. But the structure of the opportunity is why the company has been willing to invest in an indication others have retreated from.

Several conditions have to hold for the commercial case to work:

• The phase 2 effect has to survive a larger, longer phase 3 program, where placebo responses and adherence to the gluten-free diet both become harder to control.
• Regulators have to agree on what constitutes a clinically meaningful endpoint in a disease where symptoms and histology do not always move together.
• Payers have to accept a branded biologic in a condition currently managed at no drug cost, through diet alone.
• Safety over long-term dosing has to be acceptable in a population that is otherwise not seriously ill much of the time.

Interleukin-15 blockade is also being explored across other immune-mediated conditions, so a validated antibody has optionality beyond celiac. That is the part of the story that turns a single readout into a platform argument — and the part that will draw the most scrutiny, because it is also the easiest to oversell before phase 3 data exist.

What it does for a company still defined by generics

Teva is best known globally as a generics manufacturer, and the strategic question hanging over it for years has been whether it can generate enough branded, patent-protected revenue to change the shape of its earnings. Every innovative asset that advances raises the ceiling on that argument; every one that stalls sends the company back to a business where price is the main competitive weapon.

A celiac drug is an especially useful asset in that context because it would not be competing against entrenched branded incumbents. Launching into an empty category avoids the discounting dynamics that grind down margins in crowded immunology markets, at least until a competitor arrives.

The counterweight is time. A phase 2 win is the start of the expensive part, not the end of it. Phase 3 programs in gastrointestinal autoimmune disease require biopsies, long dosing periods and large enrolments, and the cash commitment lands years before any revenue does.

How the shares are positioned

Teva last traded at 36.36 in the quote feed as of the close on Friday, Sept. 4, 2026, down 0.71% from the prior close of 36.62. The session range ran from 36.13 to 36.93. Markets are closed; that is the most recent print, not a live quote.

The broader tape that day was mixed. The S&P 500 tracker (SPY) finished at $770.19, down 0.39%, and the Dow tracker (DIA) closed at $534.08, off 0.53%, while the Nasdaq 100 tracker (QQQ) ended at $718.96, up 0.18%. A sub-1% move in Teva against that backdrop is not the signature of a stock being repriced for a new blockbuster. It reads as a market waiting for detail — endpoint definitions, effect sizes, safety profile, phase 3 design — before assigning value to an asset that is still several years from any launch decision.

What to watch next

The next informative signals are procedural rather than dramatic. The first is the full presentation of the phase 2 data at a medical meeting or in a peer-reviewed journal, which is where the size and durability of the effect become visible rather than described. The second is whether Teva commits publicly to a phase 3 program and on what timeline, since that is the moment the company puts capital behind its own result. The third is regulatory engagement on endpoints, because in an indication with no approved therapy the approval standard itself is partly unsettled.

Until those arrive, the honest framing is narrow: a difficult target has produced a positive midstage result in a disease with no approved drug, and a company that badly needs branded growth now has one more reason to keep spending on it. That is meaningful. It is not yet a revenue line.

Key facts

• Ticker and last price: TEVA — 36.36, down 0.71%, at the close on Sept. 4, 2026
• Trial result: Phase 2 win in celiac disease for Teva's anti-interleukin-15 antibody
• Competitive position: Positioned as potential first-in-class; no approved drug treats celiac disease
• Session range: 36.13 to 36.93, prior close 36.62

Frequently asked questions

What did Teva report?

Teva Pharmaceutical said its antibody targeting interleukin-15 succeeded in a phase 2, or midstage, clinical trial in celiac disease. The company positions the asset as a potential first-in-class autoimmune blockbuster. Detailed endpoint results, effect sizes and safety data were not part of the initial disclosure, and full data would typically follow at a medical meeting or in a journal.

Why is interleukin-15 a target in celiac disease?

Interleukin-15 is a cytokine, a signalling protein that activates and sustains certain immune cells. In celiac disease it is implicated in the process by which immune cells resident in the gut lining damage the intestinal surface. Blocking it with an antibody aims to interrupt the tissue-damage step of the disease rather than the initial recognition of gluten.

Is there any approved drug for celiac disease?

No. Celiac disease is currently managed entirely through diet — strict, lifelong avoidance of gluten from wheat, barley and rye. Many patients continue to experience symptoms and intestinal damage despite believing they adhere to the diet, because trace gluten is widespread in the food supply. That gap is what makes the indication commercially attractive to drug developers.

How did Teva shares react?

Teva last traded at 36.36 at the close on Friday, Sept. 4, 2026, down 0.71% from a prior close of 36.62, with a session range of 36.13 to 36.93. That is a modest move relative to the broader market that day, suggesting investors are waiting for detailed trial data and a phase 3 commitment before repricing the asset.

What does first-in-class mean here?

First-in-class means a drug would be the first approved medicine working through its mechanism in that condition, arriving without a branded competitor already established. In celiac disease, where no drug is approved at all, that would mean launching into an empty category — avoiding the discounting pressure typical of crowded immunology markets, at least until a rival product reaches the market.

What happens next in the program?

The immediate milestones are publication or presentation of the full phase 2 data, a public commitment from Teva to a phase 3 program with a timeline, and regulatory discussions on what endpoints will support approval. Phase 3 trials in gastrointestinal autoimmune disease are large and expensive, requiring biopsies and long dosing periods, so costs precede revenue by years.

Sources

• Teva autoimmune antibody notches ph. 2 win in celiac disease — Fierce Biotech

Photo: Rachel Claire · Pexels Licence — source